DUBLIN–(BUSINESS WIRE)–Research and Markets has actually announced the addition of the “Relapsed Acute Myeloid Leukemia – Pipeline Review, H1 2016” report to their offering.
This report supplies comprehensive short article regard the therapeutic improvement with regard to Relapsed Acute Myeloid Leukemia, finish along with comparative analysis at numerous stages, therapeutics assessment by drug target, mechanism of action (MoA), path of administration (RoA) and molecule type, along along with latest updates, and featured news and press releases. It likewise reviews crucial users associated with the therapeutic improvement with regard to Relapsed Acute Myeloid Leukemia and unique features regard late-phase and discontinued projects.
The report raises decision making capabilities and recommendations to make efficient contrarily strategies to obtain competitive advantage. It strengthens R&D pipelines by determining brand-new targets and MOAs to create first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Relapsed Acute Myeloid Leukemia Overview
- Therapeutics Development
- Pipeline product and services with regard to Relapsed Acute Myeloid Leukemia – Overview
- Pipeline product and services with regard to Relapsed Acute Myeloid Leukemia – Comparative Analysis
- Relapsed Acute Myeloid Leukemia – Therapeutics under improvement by Companies
- Relapsed Acute Myeloid Leukemia – Therapeutics under Investigation by Universities/Institutes
- Relapsed Acute Myeloid Leukemia product and services Glance
- Late phase Products
- Clinical phase Products
- Early phase Products
- Relapsed Acute Myeloid Leukemia – product and services under improvement by Companies
- Relapsed Acute Myeloid Leukemia – product and services under Investigation by Universities/Institutes
- Relapsed Acute Myeloid Leukemia – Organizations associated with Therapeutics Development
- 4SC AG
- AbbVie Inc.
- Actinium Pharmaceuticals, Inc.
- Agios Pharmaceuticals, Inc.
- Amgen Inc.
- Arog Pharmaceuticals, Inc.
- Array BioPharma Inc.
- Astellas Pharma Inc.
- AVEO Pharmaceuticals, Inc.
- Bellicum Pharmaceuticals, Inc.
- BioLineRx, Ltd.
- BioSight Ltd.
- Boehringer Ingelheim GmbH
- Boston Biomedical, Inc.
- Bristol-Myers Squibb Company
- Calithera Biosciences, Inc.
- Celgene Corporation
- Cellceutix Corporation
- Cornerstone Pharmaceuticals, Inc.
- CTI BioPharma Corp.
- Daiichi Sankyo Company, Limited
- Eisai Co., Ltd.
- EpiZyme, Inc.
- Exelixis, Inc.
- F. Hoffmann-La Roche Ltd.
- FORMA Therapeutics, Inc.
- Fujifilm Corporation
- GlaxoSmithKline Plc
- GlycoMimetics, Inc.
- Igenica Biotherapeutics, Inc.
- Incyte Corporation
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Johnson & Johnson
- JW Pharmaceutical Corporation
- Karyopharm Therapeutics, Inc.
For much more short article browse through http://ift.tt/1TGZ5Qo
